Abstract
Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Current Pharmaceutical Design
Title: Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases
Volume: 17 Issue: 31
Author(s): Daniela M. Arduino, A. Raquel Esteves, Diana F.F. Silva, Diogo Martins-Branco, Daniel Santos, Diana F. Gomes Pimentel and Sandra M. Cardoso
Affiliation:
Keywords: Macroautophagy, proteasome, ubiquitin, protein aggregates, mitochondria, Parkin-mediated mitophagy, neurodegeneration, oxidative stress, Aβ peptide, apoptosis
Abstract: Cellular homeostasis relies on quality control systems so that damaged biologic structures are either repaired or degraded and entirely replaced by newly formed proteins or even organelles. The clearance of dysfunctional cellular structures in long-lived postmitotic cells, like neurons, is essential to eliminate, per example, defective mitochondria, lipofuscin-loaded lysosomes and oxidized proteins. Short-lived proteins are degraded mainly by proteases and proteasomes whether most long-lived proteins and all organelles are digested by autophagy in the lysosomes. Recently, it an interplay was established between the ubiquitin-proteasome system and macroautophagy, so that both degradative mechanisms compensate for each other. In this article we describe each of these clearance systems and their contribution to neuronal quality control. We will highlight some of the findings that provide evidence for the dysfunction of these systems in Alzheimers and Parkinsons diseases. Ultimately, we provide an outline on potential therapeutic interventions based on the modulation of cellular degradative systems.
Export Options
About this article
Cite this article as:
M. Arduino Daniela, Raquel Esteves A., F.F. Silva Diana, Martins-Branco Diogo, Santos Daniel, F. Gomes Pimentel Diana and M. Cardoso Sandra, Therapeutic Intervention at Cellular Quality Control Systems in Alzheimers and Parkinsons Diseases, Current Pharmaceutical Design 2011; 17 (31) . https://dx.doi.org/10.2174/138161211798072481
DOI https://dx.doi.org/10.2174/138161211798072481 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Naturally Occurring and Synthetic Peptides Acting on Nicotinic Acetylcholine Receptors
Current Pharmaceutical Design Selenium Deficiency in Soils and Crops and its Impact on Animal and Human Health
Current Nutrition & Food Science Nitric Oxide, Epileptic Seizures, and Action of Antiepileptic Drugs
CNS & Neurological Disorders - Drug Targets Level of Knowledge About Alzheimer's Disease Among Nursing Staff in Suzhou and its Influencing Factors
Current Alzheimer Research Conformational Changes of the Protein Domains Upon Binding with Carbon Nanotubes Studied by Molecular Dynamics Simulations
Current Physical Chemistry Editorial [ The Importance of Raising the Profile of Alcohol Hangover Research ]
Current Drug Abuse Reviews Epigenetics in Brain Tumors: HDACs Take Center Stage
Current Neuropharmacology Editorial (Hot Topic: Palmitoylethanolamide: Biochemistry, Pharmacology and Therapeutic Use of a Pleiotropic Anti-Inflammatory Lipid Mediator)
CNS & Neurological Disorders - Drug Targets Synthesis and Biological Evaluation of Triazole-Vanillin Molecular Hybrids as Anti-Cancer Agents
Current Bioactive Compounds Opportunities to Improve the Prevention and Treatment of Cervical Cancer
Current Molecular Medicine Time-Controlled Pulsatile Delivery Systems for Bioactive Compounds
Recent Patents on Drug Delivery & Formulation Dantrolene : From Malignant Hyperthermia to Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Medicinal Chemistry Nitric Oxide Mimetic Molecules as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Euthyroid Depression: The Role of Thyroid Hormone
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Development of HIV Reservoir Targeted Long Acting Nanoformulated Antiretroviral Therapies
Current Medicinal Chemistry Targeting Heparan Sulfate Proteoglycans and their Modifying Enzymes to Enhance Anticancer Chemotherapy Efficacy and Overcome Drug Resistance
Current Medicinal Chemistry The Discovery of Epidepride and Its Analogs as High-Affinity Radioligands for Imaging Extrastriatal Dopamine D2 Receptors in Human Brain
Current Pharmaceutical Design Does Mechanism of Drug Action Matter to Inform Rational Polytherapy in Epilepsy?
CNS & Neurological Disorders - Drug Targets